Search Results
10
Everything
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
March 20, 2025 08:30 ET
|
Stemline Therapeutics, Inc.
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around...
Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer
February 21, 2025 08:30 ET
|
Stemline Therapeutics, Inc.
Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help...
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
January 10, 2025 09:00 ET
|
Stemline Therapeutics, Inc.
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312)...
STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm
May 19, 2020 12:23 ET
|
Bragar Eagel & Squire
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
ALERT: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors of Important Deadline in First Class Action Filed by Firm - STML
March 13, 2017 18:07 ET
|
The Rosen Law Firm PA
NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Stemline Therapeutics, Inc. securities (NASDAQ:STML): (1) pursuant and/or...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML
February 27, 2017 18:11 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc....